Category: Policy

HTA Toolkit for Patient organizations
ARC Launches HTA Toolkit for Patient Advocates
ARC has published a Health Technology Assessment Toolkit to equip patients and patient groups within Europe, as well as globally, with the tools to advocate on behalf of themselves and other patients for access to new treatments. (more…)
Read More
FDA Amyloidosis Forum
Report from the Amyloidosis Forum’s Initial Meeting at FDA
The inaugural Amyloidosis Forum took place on November 12th, 2019 at FDA’s White Oak Campus in Silver Spring, MD. We could not have hoped for a better turnout, a more spirited and productive discussion. (more…)
Read More
ARC’s Advocates work Capitol Hill
Our ARC team of amyloidosis patients, caregivers and ARC staff took part as advocates in key activities during the week of Rare Disease Day, which is held on February 28th each year.  (more…)
Read More
Join us for Rare Disease Week: Act Now!
Rare disease day takes place on February 28th of each year. The entire week provides a unique opportunity to advocate and raise awareness of key policy issues that affect amyloidosis patients. (more…)
Read More
21st Century Cures Act
21st Century Cures Holds Promise for Amyloidosis
On December 13th, President Obama signed into law the 21st Century Cures Act, a game-changing bill for medical innovation. We are very grateful to Representatives Fred Upton (R-MI) and Diana DeGette (D-CO), as well as members of their staff, for...
Read More

AMYLOIDOSIS RESEARCH CONSORTIUM, INC.
320 Nevada Street, Suite 210 Newton, MA 02460 USA | 617-467-5170
arc@arci.org

ARC is a 501(c)(3) nonprofit organization